Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
PHILADELPHIA, June 01, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at or attend several important investment conferences this month.
Specifically, company management will present at:
- Jefferies 2017 Healthcare Conference on Tuesday, June 6, at 4:00 p.m EDT, at the Grand Hyatt in New York
- Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, at 4:00 p.m. PDT, at the Terranea Resort in Rancho Palos Verdes, Calif.
Company management will also participate in the J.P. Morgan European Healthcare Conference on Thursday, June 22, in London.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] (215) 282-7470
